RxDoctor Payments Data

Sarah Luebker, DO

Rheumatology · Batesville, ARNPI 1134614852

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Amgen at 29.6% of the total. That places this record below the midpoint for rheumatology clinicians in AR, where the typical reported total is $4,419.

$2,637in general payments, 2019–2025

Across 158 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$781
  • AbbVie$535
  • UCB, Inc.$288
  • Mallinckrodt Hospital Products Inc.$209
  • Johnson & Johnson$148
  • Novartis$135
  • plus $542 from 12 others

What the payments were for

  • Food & beverage$2,637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,637 in reported general payments places this provider in the 45th percentile of 48 rheumatology providers in Arkansas.

See all rheumatology providers in Arkansas

Medicare billing

Part B allowed, 2024
$55,987
Medicare patients
276
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib30$185,988
Humira(Cf) PenAdalimumab20$135,255
Enbrel SureclickEtanercept13$95,646
Hydroxychloroquine Sulfate129$3,538
MethotrexateMethotrexate Sodium117$2,437
Leflunomide47$1,798
Azathioprine11$1,775
Prednisone123$702
Sulfasalazine40$679
Colchicine19$591
Allopurinol34$238
Alendronate Sodium21$166
Folic Acid23$143
Meloxicam34$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$535$185,98830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 48 rheumatology providers in Arkansas.

Other rheumatology in Batesville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →